Watch for the New Combo HIV Meds Symtuza and Biktarvy

Symtuza and Biktarvy will be the latest once-daily, single-pill regimens for treating HIV.

Think of these as new complete HIV regimens in one help improve efficacy due to improved adherence.

Symtuza (sim-TOO-zah, darunavir/cobicistat/emtricitabine/tenofovir alafenamide) will be a first-line option for treatment-naive patients or for those switching from other HIV regimens.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote